Recent Advancement and Structure Activity Paradigm of Benzothiazoles: A Classical Review for Biological Screening of Different Diseases

Abstract

Heterocyclic compounds and their analogues have been extensively studied for their diverse pharmacological properties, including antimicrobial, anti-malarial, anti-inflammatory, anti-tubercular, anti-diabetic, and anti-neoplastic activities. The benzothiazole nucleus, despite its simple and compact structure, serves as a privileged scaffold in medicinal chemistry, demonstrating a remarkable spectrum of biological activities. This review consolidates recent advancements in the chemistry of benzothiazoles, focusing on the synthesis, structural modifications, and the resultant Structure-Activity Relationship (SAR) that underpin their biological efficacy. Significant structural modifications have revealed the potent activity of benzothiazole derivatives against various microbial strains and cancer cell lines. This summary primarily focuses on the benzothiazole core and its substituted analogues, elucidating their diverse biological profiles and potential as leads for future therapeutic agents.

Keywords

Introduction

Fig.1. Variou types of heterocyclic components

1. 2. Chemistry of Benzothiazole

Fig 2

Benzothiazole is a fused heterocyclic aromatic compound, comprising a benzene ring fused with a thiazole ring at the 4 and 5 positions, forming the 1,3-benzothiazole nucleus. It is considered a "privileged scaffold" in drug discovery due to its diverse pharmacological profile [21-23]. Thiazole itself, first described by Hantzsch and Waber in 1887, shares properties with pyridine and thiophene [24].

   

 

1. 3. Structure, Molecular Formula, and Properties

IUPAC Name: 1,3-benzothiazole

Fig. 5

Molecular Formula: C?H?NS

Molecular Weight: 135.19 g/mol

Physical Properties: Pale yellow crystalline solid; Melting point: ~48-50°C; Boiling point: ~230-232°C; Slightly soluble in water, soluble in organic solvents like ethanol and chloroform.

Chemical Properties: Aromatic in nature; the nitrogen in the thiazole ring is weakly basic. It can react with aldehydes/ ketones and is also known by synonyms like Benzosulfonazole.

1. 4. Structure-Activity Relationship (SAR) of Benzothiazole

 

• The presence of hydrophobic moieties enhances the cytotoxic action of benzothiazole analogues against cancer cell lines. Substitutions with amino, hydroxyl, and chloro groups often lead to higher anticancer activity [25].
• Strong anti-inflammatory and antibacterial properties are frequently associated with mercapto (-SH) and hydrazine groups attached at the 2-position of the benzothiazole ring [26].
• The substituent at the 2-position of aminobenzothiazole is crucial for antitumor activity. Chloro-substituted derivatives often show more promising susceptibility to cancer cell lines compared to fluoro-substituted ones. Heterocyclic rings like pyrazoline and thiazole attached at this position generally confer moderate activity [27-31].
• Antibacterial and antifungal activities of 2-mercaptobenzothiazole are enhanced by electron-withdrawing groups like chloro (-Cl) or methoxy (-OCH?) at the para position of the attached aryl ring [32].

Table 2: Synthetic procedures for benzothiazole derivatives: an overview [35]

Synthesis Technique	Key Reagents/ Conditions	Yield (%)	Advantages	Limitations
Catalyst-driven Methods	Transition metal complexes (Pd, Cu), specific solvents/ temps.	60-90	High selectivity, functional group tolerance.	Costly catalysts, complex setups.
Classical Cyclization	*o*-Aminothiophenol + Carboxylic acid/ aldehyde.	60-85	Simple, direct access to core structure.	Harsh conditions, longer times.
Microwave-Assisted	*o*-Aminothiophenol + aldehydes, solvent, MW irradiation.	80-95	Rapid reactions, high efficiency, less solvent.	Requires specialized equipment.
Oxidative Cyclization	*o*-Aminothiophenol + ketones, oxidant (e.g., I?, O?).	50-90	Metal-free conditions, good functional group compatibility.	Can require stoichiometric oxidants.

Figure 9.   Benzothiazole derivatives' effectiveness in vitro and in vivo [36]

3. 

   

 

 

    

 

Table 3: Modes of anti-neoplastic action for benzothiazole derivatives [54]

Mechanism of Action	Impact on Cancer Cells
DNA Topoisomerase Inhibition	Interferes with DNA replication, causing DNA damage and cell death.
Apoptosis Induction	Triggers mitochondrial dysfunction, caspase activation, and DNA fragmentation.
Tubulin Polymerization Inhibition	Disrupts microtubule dynamics, leading to mitotic arrest.
Angiogenesis Inhibition	Reduces VEGF expression, starving tumors of nutrients.
Cell Cycle Arrest	Induces arrest at specific phases (e.g., G1/S) by modulating cyclins/ CDKs.
Modulation of Signaling Pathways	Inhibits key pathways like EGFR, JAK/STAT, impairing growth/ survival signals.

 

Table 4: Comparative effectiveness of benzothiazole compounds versus recognized anti-cancer treatments [56]

Compound / Class	Target Cancer Type	IC?? (µM) Range	Primary Mode of Action	Key Observation
C-Benzothiazole Analogues	Colorectal	0.7 - 0.8	Angiogenesis Inhibition	Potentially more effective than Bevacizumab.
Benzothiazole Derivative A	Breast	~1.2	Apoptosis Induction	More potent than Doxorubicin in models.
D-Benzothiazole Derivative	Melanoma	1.4 - 1.5	Topoisomerase Inhibition	Shows better efficacy than Dacarbazine.
Paclitaxel (Standard)	Lung	1.7 - 1.8	Microtubule Stabilization	Established drug with resistance issues.
Doxorubicin (Standard)	Breast	3.4 - 3.5	Topo-II Inhibition & Intercalation	Broad-spectrum but with cardiotoxicity.

2.2. Anti-microbial Activity Benzothiazoles exhibit significant activity against a range of pathogens. Kumbhare et al. reported antimicrobial activity for 1-(2-aminobenzothiazole-6-oxy) derivatives [57]. Corbo et al. found 2-aminobenzothiazole analogues to be active against Candida species [58]. Derivatives like 2-(5-substituted-1,3,4-oxadiazole-2-yl)-1,3-benzothiazoles and benzothiazole-linked thiazolidinones have shown promising results against Gram-positive and Gram-negative bacteria [61,62].

2.3. Anti-inflammatory Activity: Electron-donating groups (Cl, OCH?) at the 4/5 positions of 2-aminobenzothiazole enhance anti-inflammatory activity [63]. Shafi et al. synthesized bis-heterocycles incorporating 2-mercaptobenzothiazole via click chemistry, which showed potent activity in carrageenan-induced paw edema models and COX inhibition assays [64]. 2-Benzylbenzo[d]thiazole-6-sulfonamides also demonstrated significant anti-inflammatory effects [65].

2.4. Anti-tubercular Activity: Benzothiazole derivatives are promising agents against Mycobacterium tuberculosis, including multidrug-resistant strains. Shaik et al. reported potent in-vitro activity for 3-(4-(6-methylbenzo[d]thiazol-2-yl)phenyl)quinazolin-4(3H)-ones against H37Rv [67]. Dinakaran et al. identified 3-nitro-2-substituted-5,12-dihydro-5-oxobenzothiazolo[3,2-a][1,8]naphthyridine-6-carboxylic acids with excellent MIC values [70].

2.5. Anti-malarial Activity: Benzothiazole-pyridine hybrids based on the amodiaquine scaffold have shown potent antiplasmodial activity against chloroquine-resistant (W2) and sensitive (3D7) strains of Plasmodium falciparum [71]. 2-Substituted-6-nitro and 6-aminobenzothiazoles also demonstrated significant potential as anti-malarial leads [72].

2.6. Anti-diabetic Activity: Targeting diabetes, N-(6-substituted-1,3-benzothiazol-2-yl) benzenesulfonamides showed in vivo antidiabetic effects and inhibition of 11β-HSD1 and PTP-1B enzymes [73]. Ethyl 2-(6-substituted benzo[d]thiazol-2-ylamino)-2-oxoacetates were identified as PTP-1B inhibitors, reducing plasma glucose levels in normoglycemic and oral glucose tolerance tests [75].

3. RESULTS AND DISCUSSION

This review synthesizes data demonstrating that the benzothiazole nucleus is a cornerstone in medicinal chemistry due to its structural simplicity and profound biological versatility. The SAR studies conclusively show that strategic substitutions at the 2-, 5-, and 6-positions of the benzothiazole ring drastically modulate activity, potency, and selectivity across different therapeutic areas. For instance, hydrophobic and electron-donating groups enhance anticancer and antimicrobial activities, respectively. Synthetic advancements, particularly microwave-assisted and metal-free oxidative methods, have provided efficient, greener routes to diverse libraries of benzothiazole derivatives. Mechanistic insights reveal that these compounds act through targeted pathways, including enzyme inhibition (topoisomerase, PTP-1B), apoptosis induction, and disruption of cellular structures (tubulin). While the promise is significant, challenges remain in optimizing pharmacokinetic properties and selectivity to minimize off-target effects. Future research integrating computational modeling, pharmacogenomics, and nanoparticle-based delivery systems could unlock the full therapeutic potential of benzothiazole derivatives, transforming them from potent in-vitro agents into effective clinical drugs.

4. CONCLUSION

Benzothiazoles represent a versatile and indispensable heterocyclic system in drug discovery. As evidenced by the extensive literature, subtle structural modifications yield derivatives with significant and diverse biological activities, including anticancer, antimicrobial, anti-inflammatory, antitubercular, antimalarial, and antidiabetic effects. The continuous evolution of synthetic strategies facilitates the exploration of novel chemical space around this core. The clear structure-activity relationships provide a robust framework for the rational design of next-generation therapeutic agents. Therefore, the benzothiazole scaffold undoubtedly remains a highly promising and fertile ground for developing new lead compounds to address various unmet medical needs.

REFERENCES

1. Gupta R. R., Kumar M., Gupta V. Heterocyclic Chemistry, Springer Publication, 1998; 1: 13-14.
2. Piscitelli F, Ballatore C, Smith A. Bioorg Med Chem Lett. 2010;20:644-8.
3. Shivaraj H, Gazi S, Patil S, et al. Asian J Res Chem. 2010;3(2):421-7.
4. Gilchrist T.E. Heterocyclic Chemistry, 3rd Ed., Longman, 1992.
5. Luo-Ting Yu et al. Molecules. 2012;17:3933-44.
6. Siddiqui N et al. Asian J Biomed Pharm Sci. 2012;2(10):8-17.
7. Kaur A et al. Res J Pharm Biol Chem Sci. 2012;3(4):847.
8. Himaja M. et al. Int Res J Pharm. 2011;2(1):114-7.
9. Di Giorgio C et al. Antimicrob Agents Chemother. 2002;46(8):2588–94.
10. Singh S et al. The Pharma Research. 2009;1(1):192-8.
11. Mahran MA et al. Molecules. 2007;12:622-33.
12. Sekar N. et al. Arab J Chem. 2012.
13. Verma AK et al. Indian J Pharm Biol Res. 2014;2(3):84-9.
14. Arora P et al. J Chem Pharm Res. 2010;2(4):317-23.
15. Mariappan G et al. J Korean Chem Soc. 2012;56(2).
16. Keri RS et al. Eur J Med Chem. 2015;89:207-51.
17. Asiri YI et al. J Pharm Pharmacol. 2020;72(11):1459-80.
18. el-Sherbeny, M.A. Arzneimittel forschung. 2000;50(9):848-85.
19. Racane, L. et al. ChemInform. 2002;26:33.
20. Chohan, Z.H.; Supuran, C.T. Main Group Met Chem. 2002;25:291-6.
21. Achson A. An Introduction to the Chemistry of Heterocyclic Compounds, 3rd ed., Willy Intersciences, India, 2009.
22. Shaista A, Amrita P. Int J Pharm Sci Res. 2017;8(12):4909-29.
23. Ahmad K, Malik MS, Syed MAH. Expert Opin Ther Pat. 2015;25(3):335-49.
24. Gilchrist T.E. Heterocyclic Chemistry, 3rd Ed., Longman, 1992.
25. Wang M et al. Bioorg Med Chem. 2006;14:8599-607.
26. Shivganga H. Asian J Res Chem. 2010;3(2):421-7.
27. Piscitelli F et al. Bioorg Med Chem Lett. 2010;20:644-8.
28. Reddy P, Lin Y, Chang H. Arkivoc. 2007;xvi:113-22.
29. Heo Y et al. Tetrahedron Lett. 2006;47:3091-4.
30. Rauf A, Gangal S, Sharma S. Indian J Chem. 2005;47B:601-5.
31. Amnekar N, Bhusari K. Dig J Nanomater Bios. 2010;5:177-84.
32. Murthi Y, Pathak D. J Pharm Res. 2008;7(3):153-5.
33. Sharma PC et al. Appl Mater Today. 2020;20:100783.
34. Hunasnalkar SG et al. Asian J Res Chem. 2010;3(2):421-7.
35. Sharma PC et al. Curr Top Med Chem. 2017;17(2):208–37.
36. Qiao JX et al. ChemMedChem. 2014;9(10):2327–43.
37. Folgueiras-Amador AA et al. Chemistry. 2018;24(2):487-91.
38. Amnekar N, Bhusari K. Dig J Nanomater Bios. 2010;5:177-84.
39. Bose, D.S.; Idrees, M. J Org Chem. 2006;71(21):8261-3.
40. Rajak H et al. RGUHS J Pharm Sci. 2013;03:14-20.
41. Zhang XZ et al. J Chem Res. 2012;36(8):489-91.
42. Appukkuttan P et al. Chem Soc Rev. 2010;39(5):1467-77.
43. Praveen C et al. J Chem Sci. 2012;124:609-24.
44. Zhang XZ et al. J Chem Res. 2012;36(8):489-91.
45. Murthi Y, Pathak D. J Pharm Res. 2008;7(3):153-5.
46. Kreysa, F.J. et al. J Am Chem Soc. 1951;73(3):1155-6.
47. Liao, Y. et al. Org Lett. 2012;14(23):6004-7.
48. Jordan, A. D. et al. J Org Chem. 2003;68:8693-6.
49. Stanton HLK et al. Bioorg Med Chem. 2008;16:3626-31.
50. Paramashivappa R et al. Bioorg Med Chem Lett. 2003;13:657-60.
51. Chen JC et al. Sci China Ser B-Chem. 2008;51(2):111-9.
52. Aiello, S. et al. J Med Chem. 2008;51(16):5135-9.
53. Flavio Maina et al. PLoS One. 2012;7(10):e46738.
54. Lad NP et al. Bioorg Med Chem Lett. 2017;27(5):1319–24.
55. Wiman KG, Zhivotovsky B. J Intern Med. 2017;281(5):483–95.
56. Wilcken R et al. J Med Chem. 2013;56(4):1363–88.
57. Kumbhare, R.M.; Ingle, V.N. Indian J Chem. 2009;48B:996-1000.
58. Corbo F et al. Eur J Med Chem. 2013;64:357–64.
59. Yadav A et al. The Pharma Research. 2009;01:182-7.
60. Sharma PC, Jain S. Acta Pol Pharm Drug Res. 2008;65:551-86.
61. Rajeeva B, Srinivasulu N, Shantakumar SM. E-Journal of Chemistry. 2009;6(4):S467-S472.
62. Nagarajan A et al. Indian J Chem. 2009;48B:1577-82.
63. Hout S et al. Parasitology. 2004;129:525-42.
64. Shafi, M. M. et al. Eur J Med Chem. 2012;49:324–33.
65. Mahtab R et al. J Chem Pharm Sci. 2014;7(1):34-8.
66. Katz. J Am Chem Soc. 1953;75(3):712–14.
67. Shaik A et al. Indian J Res Pharm Biotechnol. 2014;2(6):935-42.
68. Karali N et al. Bioorg Med Chem. 2007;15:5888–5904.
69. Aridoss G et al. Eur J Med Chem. 2009;44:4199–4210.
70. Dinakaran M et al. Biomed Pharmacother. 2009;63:11–18.
71. Ongarora DSB et al. Bioorg Med Chem Lett. 2012;22(15):5046-50.
72. Kumbhare RM, Ingle VN. Indian J Chem. 2009;48B:996-1000.
73. Moreno-Díaz, R. et al. Bioorg Med Chem Lett. 2008;18(9):2871–7.
74. Venkatesh P, Pandeya SN. Int J ChemTech Res. 2009;1(4):1354-8.
75. Navarrete-Vazquez, M. et al. Eur J Med Chem. 2012;53:346–55.
76. Figure 1: Various types of heterocyclic components. Source: Gupta R. R., Kumar M., Gupta V. Heterocyclic Chemistry, Springer Publication, 1998; 1: 13-14.
77. Figure 2: Benzothiazole moiety. Source: Gilchrist T.E. Heterocyclic Chemistry, 3rd Ed., Longman, 1992.
78. Figure 3: Structure of benzothiazole. Generated based on IUPAC name.
79. Figure 4: Different biological activities of Benzothiazole analogues. Adapted from: Hunasnalkar SG et al. Asian J Res Chem. 2010;3(2):421-7.
80. Figure 5: Electrochemical synthesis pathway [37]. Adapted from Folgueiras-Amador AA et al. Chemistry. 2018;24(2):487-91.
81. Figure 6: Solvent-free microwave synthesis [38]. Adapted from Amnekar N, Bhusari K. Dig J Nanomater Bios. 2010;5:177-84.
82. Figure 7: Radical cyclization synthesis [39]. Adapted from Bose, D.S.; Idrees, M. J Org Chem. 2006;71(21):8261-3.
83. Figure 8: I?-catalyzed condensation with ketones [47]. Adapted from Liao, Y. et al. Org Lett. 2012;14(23):6004-7.
84. Figure 9: Mechanisms of action of benzothiazole derivatives. Adapted from: Wiman KG, Zhivotovsky B. J Intern Med. 2017;281(5):483–95.